Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prothena Corp Public (PRTA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Prothena Corp Public (PRTA) over the last 14 years, with Q3 2025 value amounting to $330.8 million.

  • Prothena Corp Public's Cash & Equivalents fell 3628.59% to $330.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.8 million, marking a year-over-year decrease of 3628.59%. This contributed to the annual value of $471.4 million for FY2024, which is 2382.59% down from last year.
  • Latest data reveals that Prothena Corp Public reported Cash & Equivalents of $330.8 million as of Q3 2025, which was down 3628.59% from $371.4 million recorded in Q2 2025.
  • Prothena Corp Public's 5-year Cash & Equivalents high stood at $710.4 million for Q4 2022, and its period low was $330.8 million during Q3 2025.
  • Its 5-year average for Cash & Equivalents is $528.2 million, with a median of $543.0 million in 2022.
  • Per our database at Business Quant, Prothena Corp Public's Cash & Equivalents soared by 9605.05% in 2021 and then crashed by 3628.59% in 2025.
  • Quarter analysis of 5 years shows Prothena Corp Public's Cash & Equivalents stood at $579.1 million in 2021, then rose by 22.68% to $710.4 million in 2022, then dropped by 12.89% to $618.8 million in 2023, then decreased by 23.83% to $471.4 million in 2024, then fell by 29.82% to $330.8 million in 2025.
  • Its Cash & Equivalents stands at $330.8 million for Q3 2025, versus $371.4 million for Q2 2025 and $417.9 million for Q1 2025.